BioVie Inc. (BIVI) Research

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.

Market snapshot

Symbol
BIVI
Price
$1.76
Day change
-1.68%
Market cap
$13.3M
P/E ratio
-0.67x
52-week range
1.06-10.9
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • BioVie: Long COVID trial fully enrolled – ICYMI

    BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID symptoms. Speaking with Proactive, CEO Cuong Do said the study enrolled more than 200 long COVID patients with support from major medical institutions including Yale, Mount Sinai, Mayo Clinic and Stanford.

  • BioVie: Long COVID trial fully enrolled – ICYMI

    BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment,...

  • BioVie to highlight neuro and liver disease programs in June 2 investor webinar

    BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will host an investor webinar on June 2 at 4:15 p.m. ET featuring CEO Cuong Do. The discussion will focus on...

Peer companies

  • Artelo Biosciences, Inc. (ARTL)
  • Can-Fite BioPharma Ltd. (CANF)
  • CERo Therapeutics Holdings, Inc. (CERO)
  • PMGC Holdings Inc. (ELAB)
  • Galmed Pharmaceuticals Ltd. (GLMD)
  • InMed Pharmaceuticals Inc. (INM)
  • Kazia Therapeutics Limited (KZIA)
  • Lipella Pharmaceuticals Inc. (LIPO)

Recent insider activity

  • Palumbo Joseph M — A-Award (132000 shares) on 2026-01-05
  • KIM JOANNE WENDY — A-Award (110100 shares) on 2026-01-05
  • ROGICH SIGMUND — A-Award (141100 shares) on 2026-01-05
  • ROGICH SIGMUND — A-Award (70000 shares) on 2026-01-05
  • DO CUONG V — A-Award (665300 shares) on 2026-01-05

Open BioVie Inc. (BIVI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.